HGH Fragment 176-191
A modified fragment of human growth hormone; not FDA-approved.
What it is
HGH Fragment 176-191 is the tail end of the growth-hormone molecule, promoted online for fat loss on the strength of animal and in-vitro lipolysis work. It is closely related to AOD-9604 — which is essentially this fragment stabilized — and that relationship is inconvenient for its marketing.
AOD-9604 carried the fragment hypothesis into controlled human obesity trials and failed. Fragment 176-191 itself has no published controlled human trials, so its sales pitch rests on animal data whose human translation was already tested by its stabilized sibling.
What researchers have actually studied it for
Lipolysis in animal and laboratory studies; the closely related AOD-9604 tested the concept in human trials without success.
How it works
The C-terminal 16 amino acids of hGH, carrying the molecule's lipolytic signaling region without the growth-receptor engagement — fat-cell effects in rodents and cell culture, no IGF-1 axis involvement. Identical conceptual territory to AOD-9604, minus the stabilizing modification and minus the trials.
The molecule itself
hGH 176-191 — the unstabilized version of the same C-terminal tail AOD-9604 modified, 16 residues of lipolytic-region excerpt with no growth-receptor activity. Chemically it is AOD-9604 minus the stabilizing tyrosine; evidentially it is AOD-9604 minus the trials.
Where it came from
Fragment studies from the 1970s–90s mapped hGH's regions and found the fat-active tail, work that fed directly into AOD-9604's development. When that program failed and ended, the unstabilized fragment lived on in research-chemical catalogs, marketed on the pre-failure literature.
The timeline
1970s–90s
Fragment-mapping studies locate hGH's fat-active tail.
2000s
The stabilized analog (AOD-9604) carries the hypothesis into trials — and fails.
2010s+
The raw fragment persists in research-chemical catalogs on pre-failure literature.
What the research record actually contains
- Rodent and in-vitro lipolysis studies of the fragment region.
- No published controlled human trials of Fragment 176-191 itself.
- The stabilized analog's failed human obesity program — the closest thing to a human answer, and it was negative.
What could change this assessment
None — no program, no thread, no plausible sponsor. Its persistence is pure catalog inertia.
What's known about risks
No human characterization. The AOD-9604 program suggests the fragment class is tolerable; sourcing and contents of gray-market vials are their own uncontrolled risk.
Where it stands legally
Never approved; research-chemical channel only.
Worth asking a licensed provider
- 1.What distinguishes this from AOD-9604, whose human trials failed?
- 2.Is there any human evidence at all connecting this fragment to fat loss?
- 3.What evidence-backed fat-loss options should we be discussing instead?
Common claims, corrected
“It's different enough from AOD-9604 that the failed trials don't apply.”
Reality: It's the same fragment without stabilization — if anything a weaker version of the molecule whose human test came back null.
“No trials means untested potential.”
Reality: Its concept was tested via its stabilized twin. 'Untested' here means 'the test it dodged already happened.'
HGH Fragment 176-191 FAQ
What is the difference between HGH Fragment 176-191 and AOD-9604?
AOD-9604 is essentially this fragment with a stabilizing modification. AOD-9604's human obesity trials failed to show meaningful weight loss — context any Fragment 176-191 claim has to answer for.
Does HGH Fragment 176-191 burn fat in humans?
No controlled human trials of the fragment exist, and the human test of the underlying idea (via AOD-9604) came back negative. The honest answer is 'no demonstrated human effect.'
Is HGH Fragment 176-191 the same as HGH?
No — it's a 16-amino-acid slice of the 191-amino-acid hormone, without GH's growth signaling. It neither is HGH nor carries HGH's evidence.
Is Fragment 176-191 stronger than AOD-9604?
No data suggests so, and stability chemistry argues the opposite. The comparison mostly exists so vendors can differentiate two names for one idea.
Does it raise IGF-1 or affect growth?
No — the tail lacks GH-receptor activity by design, which is the one claim about it that's well-founded. It neither is HGH nor acts like it.